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ABSTRACT: Studies on the further development of the sequential glycosylations of the vancomycin aglycon catalyzed by the
glycosyltransferases GtfE and GtfD and the observation of unusual, perhaps unexpected, aglycon substrate substituent eﬀects on
the rate and eﬃciency of the initial glycosylation reaction are reported.
T
he glycopeptide antibiotics are the most important class of
drugs used for the treatment of resistant bacterial
infections that include those caused by methicillin-resistant
Staphylococcus aureus (MRSA).
1,2 After more than 50 years of
clinical use, the emergence of vancomycin-resistant Gram-
positive pathogens, including not only vancomycin-resistant
Enterococci (VRE)
3 but also the more recent vancomycin-
resistant S. aureus (VRSA),
4 presents an imminent challenge to
public health at a time few new antibiotics are being developed.
This has led to renewed interest in the search for additional
eﬀective treatments for such resistant organisms that possess
the long-term durability of the two clinically used glycopeptide
antibiotics, vancomycin
5 (Figure 1) and teicoplanin.
1,2,6
In recent eﬀorts, we reported the total syntheses of two
vancomycin aglycon analogues
7,8 designed to address the
underlying molecular basis of resistance to the glycopeptide
antibiotics.
9 Rational single atom changes to the vancomycin
binding pocket designed to achieve dual binding to D-Ala-D-Ala
and D-Ala-D-Lac were introduced to reinstate antimicrobial
activity against vancomycin-resistant bacteria while maintaining
activity against vancomycin-sensitive bacteria.
10,11 The success
of the eﬀorts set the stage for not only ongoing continued
studies that might further improve their activity and potency
12
but also the subsequent eﬀorts needed to complete the
peripheral tailoring of the aglycons with introduction of the L-
vancosaminyl-1,2-D-glucosyl disaccharide. Although the at-
tached carbohydrate does not impact in vitro antimicrobial
activity or signiﬁcantly alter target D-Ala-D-Ala or D-Ala-D-Lac
binding aﬃnities responsible for inhibition of transpeptidase-
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Figure 1. Structure of vancomycin.
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Terms of Usemediated bacterial cell wall cross-linking, the nature of the
appended carbohydrate aﬀects in vivo activity, increasing its
water solubility and inﬂuencing its PK and distribution
properties. It has also been suggested that the vancomycin
carbohydrate may mediate a second, though less potent,
mechanism of action through direct inhibition of trans-
glycosylase enzymes.
13
For vancomycin, the carbohydrate introduction has been
approached by using either chemical
14−16 or enzymatic
17−20
glycosylations for sequential introduction of the glucose and
vancosamine sugars located on the central residue of the
aglycon or pseudoaglycon, respectively. Herein, we report
studies on the further development of the sequential
glycosylations of the vancomycin aglycon catalyzed by the
glycosyltransferases GtfE and GtfD and the observation of
unusual, perhaps unexpected, substrate substituent eﬀects on
the rate and eﬃciency of the initial glycosylation reaction that
were conducted as a prelude to their use with our pocket
modiﬁed vancomycin aglycon analogues.
Although each enzymatic step has been examined analytically
(GtfE with UDP-glucose
17a and GtfD with TDP-vancosami-
ne
17b) and alternative monosaccharides have been incorporated
at each site,
17−19 and even spacer linked carbohydrate
attachments
21 have been examined, a preparative synthesis of
vancomycin from the aglycon using the enzymatic approach has
not been detailed. This can be attributed to the challenges at
the time the enzymes were characterized of converting
vancosamine, a 2-deoxy sugar, to the thermodynamically less
stable but requisite β-anomer of either thymidine or uridine
diphosphoryl-β-2-vancosamine (TDP- or UDP-vancosamine)
required of the GtfD cosubstrate.
17 As such and in combination
with our earlier eﬀorts that provided a total synthesis of the
vancomycin aglycon (2),
22 the eﬀorts herein also constitute our
completion of a total synthesis of vancomycin itself.
The recombinant glycosyltranferases GtfE and GtfD from
the vancomycin producing strain of A. orientalis (ATCC19795)
were expressed in E. coli from the corresponding constructs
17a
and were puriﬁed to homogeneity (His6 tag). Synthetic UDP-
vancosamine, possessing the requisite β-anomer stereochemis-
try, was prepared adapting a procedure recently described by
Kahne
23 and used to access TDP-vancosamine, albeit with
modiﬁcations to the synthetic route that incorporate uridine
versus thymidine (Supporting Information). With use of the
puriﬁed enzymes and the synthetic glycosyl donors UDP-
glucose
24 (for GtfE) and UDP-vancosamine (for GtfD),
conditions were optimized for the two sequential glycosylations
of vancomycin aglycon (2) as well as the synthetic derivatives
3−5,
25 bearing modiﬁcations to the C- and N-termini of the
aglycon (Scheme 1).
Of the two glycosylation reactions, the initial GtfE-catalyzed
incorporation of glucose using UDP-glucose exhibited the
greatest aglycon substrate sensitivity and the least eﬀective
substrate was 3, bearing a C-terminus hydroxymethyl group.
Consequently, optimization eﬀorts focused on this glycosyla-
tion reaction, examining simultaneously both the vancomycin
aglycon (2) and substrate 3 (37 °C). As originally reported,
17a
Tricine (pH 9.0, 75 mM) served as a most satisfactory buﬀer
although Tris (pH 9.0, 75 mM) was essentially equally eﬀective,
whereas reactions run in phosphate buﬀer (pH 8.0, 75 mM)
were found to proceed at roughly half the rate and eﬃciency as
Tricine. Although GtfE was originally reported to exhibit a
stringent requirement for use at pH 9−10,
26 Tricine (pH 8.5)
also supported the reaction eﬀectively. Added detergents
(Triton X-100, CHAPS, Tween 20) were counterproductive,
and bovine serum albumin (BSA)
17,18 did not improve or alter
the rate of the reactions examined with 2 and 3 during the
optimization; thus, neither was employed in the optimized
conditions. Increased amounts of glycosyl donor (4 mM UDP-
glucose, typically used at 2 mM) did not improve the
conversion with 3 which remained slow even with the
optimized conditions. Additionally, it was found that the
reaction tolerates added DMSO
14c (≤10% v/v), and this can be
used to dissolve less soluble substrates. The added reductant
tris(2-carboxyethyl)phosphine (TCEP, 2 mM) was crucial, and
the glycosylations failed to proceed in its absence.
17,18 The use
of a polyol additive (glycerol, 5% v/v) productively served as an
enzyme stabilizer, prolonging enzymatic activity.
18 Finally,
although recent studies that we have conducted indicate the
MgCl2
18 is not needed for the reaction,
17 our optimization
studies were conducted with its presence (1 mM). The net
result is that our ﬁnal conditions for the initial GtfE-catalyzed
reaction represent a blend of the original conditions detailed by
Walsh
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glycosylation reaction is shown in Figure 2 when enlisting the
optimized conditions on an analytical scale not only with
vancomycin aglycon (2) and its C-terminus hydroxymethyl
derivative 3 but also with the N-terminus Boc derivative 4 and
the C-terminus methyl ester 5. Whereas Boc protection of the
N-terminus amine had no eﬀect on the rate and eﬃciency of
the reaction analogous to reports of the use of the
corresponding N-Alloc derivative,
17d the substrate solubility
did beneﬁt from added DMSO (10% v/v). By contrast,
glycosylation of the methyl ester 5 proceeded signiﬁcantly more
slowly, behaving much more like 3 but only slightly better, and
added DMSO (10% v/v) in the reaction solvent system did
improve this reaction, providing 9 in approximately 8%−12%
higher conversions. However, extended reaction times led to
some competitive hydrolysis of the methyl ester under the basic
buﬀer conditions, complicating eﬀorts to eﬀectively monitor
this substrate over an extended period (i.e., >24−36 h).
Nonetheless, it is clear that modiﬁcation at the N-terminus
amine of vancomycin aglycon is well tolerated, whereas C-
terminus modiﬁcation with removal of the acidic carboxylic acid
results in a slower, less eﬀective initial glycosylation. It is
unclear if the variation in yield and rate is due to the C-
terminus modiﬁcation or to altered physical properties, but the
prospect that it is substrate induced raises interesting questions
regarding substrate recognition at the enzyme active site. It will
be interesting to further probe the tolerance of more
signiﬁcantly modiﬁed vancomycin intermediates in these
glycosylation reactions in future studies. In the case of the
hydroxymethyl substrate 3, whose reaction proceeded at the
slowest rate, preparative amounts of product 7 (55%, 48 h)
were obtained by increasing the amount of enzyme used (20 vs
5 μM).
In contrast, the second glycosylation reaction catalyzed by
GtfD using synthetic UDP-vancosamine proceeded to com-
pletion rapidly (<3 h) regardless of the vancomycin-derived
substrate (6−9), displaying no impact of either the C- or N-
terminus disposition of the substrate, and the conditions
required little optimization. Aside from incorporating the use of
glycerol (10% v/v) and reducing the amount of added BSA (0.2
vs 1 mg/mL), our reaction conditions [substrate (0.5 mM),
Tricine (pH 9.0, 75 mM), TCEP (2 mM), UDP-vancosamine
(2 mM), GtfD (5 μM), MgCl2 (2 mM), BSA (0.2 mg/mL),
glycerol (10% v/v)] remain essentially the same as originally
disclosed for use of this enzyme.
17
Finally, the preparative use of the enzymatic glycosylations
on 2−5 were conducted herein on ca. 2 mg of substrate with 1
mol % enzyme and 4 equiv of UDP-glucose or UDP-
vancosamine, reﬂecting the scale on which we anticipated
conducting the initial glycosylyations of our pocket modiﬁed
analogues of vancomycin aglycon. However, the laboratory
expression and puriﬁcation of the enzymes and the chemical
synthesis of UDP-vancosamine, along with the commercial
availability of UDP-glucose,
24 were conducted on scales that
would easily support laboratory preparations much larger (ca.
100-fold) than exempliﬁed. It is worth noting that although the
endogenous glycosyl donors for both enzymes are the TDP-
sugars,
17 UDP-sugars have been shown to be utilized as
eﬀectively as cosubstrates by both enzymes. Moreover, the
requisite NDP-sugar synthetic precursor UMP morpholidate is
commercially available,
27 whereas the corresponding activated
TMP is not, leading to our synthesis, exploration, and adoption
of UDP-vancosamine for use with GtfD.
In addition to serving as the completion of our past eﬀorts,
22
providing a total synthesis of vancomycin, the work set the
stage for glycosylation of pocket modiﬁed vancomycin
analogues needed to further explore their properties. In this
regard, the observation of unusual aglycon C-terminus eﬀects
on the rate of initial GtfE-catalyzed glycosylation and the ability
to address them by using additional enzyme under optimized
reaction conditions permitted the exploration of binding pocket
modiﬁcations initially on the more accessible earlier stage
synthetic intermediates. These and related studies will be
disclosed in due course. Most signiﬁcantly and as noted
elsewhere,
14,17,18 the enzymatic glycosylations avoid protection
and the corresponding deprotection of aglycon precursors
required of chemical procedures, providing the fully glycosy-
lated products in two steps from the fully deprotected aglycons.
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